Suchergebnisse - "Zhang, Li"

PubPharm (41)

1

Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer

enthalten in: JAMA surgery | 2024

von Li, Y. | Pan, C. | Gao, Y. | +16

2

The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

enthalten in: Cellular & molecular immunology | 2024

von Luo, F. | Li, H. | Ma, W. | +17

3

A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Zhao, Y. | Ma, Y. | Fan, Y. | +10

4

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin

enthalten in: Clinical genitourinary cancer | 2023

von Jindal, T. | Zhang, L. | Deshmukh, P. | +24

5

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR) : a randomised, open-label, pivotal phase 3 study

enthalten in: The Lancet. Oncology | 2023

von Leal, T. | Kotecha, R. | Ramlau, R. | +23

CommentIn: Lancet Oncol. 2023 Sep;24(9):946-947. - PMID 37657465

6

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Fu, Y. | Yang, B. | Cui, Y. | +18

7

The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer

enthalten in: Thoracic cancer | 2023

von Zhao, J. | Wu, Y. | Yue, Y. | +11

8

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer

enthalten in: Frontiers in immunology | 2023

von Wang, Y. | Fu, S. | Zhang, X. | +11

9

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer : a nonrandomized clinical trial

enthalten in: Frontiers in immunology | 2023

von Ni, J. | Si, X. | Wang, H. | +2

10

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors

enthalten in: Frontiers in immunology | 2023

von Gan, L. | Chen, H. | Liu, X. | +1

1
2
3
4
5
Nächster »
[5]